@moleculexyz.bsky.social
DeSci biopharma IP tokenization protocol.
Fund & shape early-stage research ideas at https://www.molecule.xyz/
Fund & shape early-stage research ideas at https://www.molecule.xyz/
The next Alzheimer's breakthrough may come from shutting off one protein.
And 1,900+ people just backed the research to test it.
$GALE closed 14.2x oversubscribed, with $712K USDC committed, to support a new approach that targets Alzheimer’s at its root: chronic inflammation.↓
And 1,900+ people just backed the research to test it.
$GALE closed 14.2x oversubscribed, with $712K USDC committed, to support a new approach that targets Alzheimer’s at its root: chronic inflammation.↓
November 25, 2025 at 12:59 AM
The next Alzheimer's breakthrough may come from shutting off one protein.
And 1,900+ people just backed the research to test it.
$GALE closed 14.2x oversubscribed, with $712K USDC committed, to support a new approach that targets Alzheimer’s at its root: chronic inflammation.↓
And 1,900+ people just backed the research to test it.
$GALE closed 14.2x oversubscribed, with $712K USDC committed, to support a new approach that targets Alzheimer’s at its root: chronic inflammation.↓
NEURON GALE is now live and trading on Molecule -- the only platform where you can track Alzheimer’s research milestones transparently and directly onchain
🧵⤵️
🧵⤵️
November 21, 2025 at 11:50 AM
NEURON GALE is now live and trading on Molecule -- the only platform where you can track Alzheimer’s research milestones transparently and directly onchain
🧵⤵️
🧵⤵️
The funding stack for science is being rebuilt.
Beyond VC and grants, a new model is forming -- where capital, incentives, and ownership move on open rails.
A shift from static institutions ➝ liquid networks of discovery ↓
Beyond VC and grants, a new model is forming -- where capital, incentives, and ownership move on open rails.
A shift from static institutions ➝ liquid networks of discovery ↓
November 14, 2025 at 12:03 AM
The funding stack for science is being rebuilt.
Beyond VC and grants, a new model is forming -- where capital, incentives, and ownership move on open rails.
A shift from static institutions ➝ liquid networks of discovery ↓
Beyond VC and grants, a new model is forming -- where capital, incentives, and ownership move on open rails.
A shift from static institutions ➝ liquid networks of discovery ↓
Today science sits in silos. Tomorrow it lives in markets.
November 9, 2025 at 2:59 AM
Today science sits in silos. Tomorrow it lives in markets.
From our screener: $AUBRAI -- the world's first BioAgent generating and owning onchain IP.
Trained on the mind of @aubreydegrey, powered by @Bioprotocol + Molecule's Proof of Invention rails.
Build for onchain science acceleration👇
Trained on the mind of @aubreydegrey, powered by @Bioprotocol + Molecule's Proof of Invention rails.
Build for onchain science acceleration👇
November 5, 2025 at 8:57 PM
From our screener: $AUBRAI -- the world's first BioAgent generating and owning onchain IP.
Trained on the mind of @aubreydegrey, powered by @Bioprotocol + Molecule's Proof of Invention rails.
Build for onchain science acceleration👇
Trained on the mind of @aubreydegrey, powered by @Bioprotocol + Molecule's Proof of Invention rails.
Build for onchain science acceleration👇
Science is still running on feudal infrastructure.
New systems are inevitable.
New systems are inevitable.
November 2, 2025 at 1:58 AM
Science is still running on feudal infrastructure.
New systems are inevitable.
New systems are inevitable.
Last week, an AI model imagined a cancer treatment -- and got it right.
This week, DrugReflector finds useful compounds 17x faster than traditional research.
The lab is turning into a thinking system --
recursive, transparent, self-improving. 👇
This week, DrugReflector finds useful compounds 17x faster than traditional research.
The lab is turning into a thinking system --
recursive, transparent, self-improving. 👇
October 28, 2025 at 2:04 PM
Last week, an AI model imagined a cancer treatment -- and got it right.
This week, DrugReflector finds useful compounds 17x faster than traditional research.
The lab is turning into a thinking system --
recursive, transparent, self-improving. 👇
This week, DrugReflector finds useful compounds 17x faster than traditional research.
The lab is turning into a thinking system --
recursive, transparent, self-improving. 👇
We’re optimizing for safety, not discovery -- producing endless variations of the same drug.
@fedichev explains how Pharma's risk aversion is dangerous for innovation.
@fedichev explains how Pharma's risk aversion is dangerous for innovation.
October 27, 2025 at 3:28 PM
We’re optimizing for safety, not discovery -- producing endless variations of the same drug.
@fedichev explains how Pharma's risk aversion is dangerous for innovation.
@fedichev explains how Pharma's risk aversion is dangerous for innovation.
An AI model just made -- and experimentally proved -- a new cancer discovery.
Google & Yale’s Cell2Sentence-Scale (27B) generated a hypothesis that turned out to be correct in living cells.
Scientific singularity is already happening. 👇
Google & Yale’s Cell2Sentence-Scale (27B) generated a hypothesis that turned out to be correct in living cells.
Scientific singularity is already happening. 👇
October 21, 2025 at 2:01 PM
An AI model just made -- and experimentally proved -- a new cancer discovery.
Google & Yale’s Cell2Sentence-Scale (27B) generated a hypothesis that turned out to be correct in living cells.
Scientific singularity is already happening. 👇
Google & Yale’s Cell2Sentence-Scale (27B) generated a hypothesis that turned out to be correct in living cells.
Scientific singularity is already happening. 👇